Lung cancer remains one of the most severe challenges to health in the UK. Each year, more than 46,000 people are diagnosed with the disease, and Roy Castle Lung Cancer Foundation is the only charity in the country dedicated solely to beating this disease,
Our aim is to improve both outcomes and patient experience; as part of our mission, we produce high-quality information materials for patients and their carers, as well as medical researchers and healthcare professionals.
A key role in this information support is played by our online ‘smart map’ which enables users to review standards of lung cancer services across the UK. The ‘smart map’ displays information gathered from authoritative sources including the National Lung Cancer Audit, compiled annually by the Royal College of Physicians. (RCP).
Patients and carers can quick and easily access to information about what they might expect at any stage of their treatment process.
Users can simply click on a area to see a ‘pop-up’ of statistics and comparisons between regions. The map displays up to date information on rates of surgery, active treatments and access to clinical strategic networks (CSN) to each area.
Following significant changes in the audit process since its launch in 2014, the Foundation recognised the need to refresh the data-set on which the map is based, and to update its look and functionality.
Lorraine Dallas, our Director of Prevention,Information and Support, is delighted with the results of this renovation.
She said: “We wanted to improve the relevance of the map and make it easier to use. To us, the most important people are lung cancer patients, and we wanted to offer them an even better tool with which to compare services across the UK. We also wanted it to have value for carers, clinicians and researchers.
“So we have included additional resources and information, such as the locations of key treatment centres and support groups that will benefit patients.”
It is a free resource, for use by anyone affected by, or with an interest, in lung cancer. The revision were carried out on behalf of the Foundation by Virgo Health communications agency, with pro-bono support from Roche, the international pharmaceutical company.